NUP62: A Potential Drug Target and Biomarker for Cancer (G23636)

Target Name: NUP62

NCBI ID: G23636

NUP62

NUP62: A Potential Drug Target and Biomarker for Cancer

Nucleoporin 62 (NUP62) is a protein that is expressed in various cell types of the human body, including neurons, astrocytes, and macrophages. It is a member of the nucleoporin family, which is a group of proteins that play a critical role in regulating the movement of RNA into the nucleus.

NUP62 is a 21-kDa protein that consists of 191 amino acid residues. It has a characteristic nucleoporin structure, with a nucleoporin domain that is responsible for its unique function. The nucleoporin domain is composed of multiple conserved structural elements, including a nucleotide-binding oligomerization domain (NBO), a deformation domain, and a carboxylic acid-rich region (CAR).

NUP62 functions as a negative regulator of microRNA (miRNA) translation. MicroRNAs are small non-coding RNAs that play a critical role in post-transcriptional gene regulation by silencing gene expression. They are produced by RNA polymerase II and can interact with various protein factors to recruit them to specific target RNAs for degradation.

NUP62 is well-studied for its role in regulating miRNA translation, and several studies have investigated its mechanisms of action. For example, one study published in the journal Nature Communication found that NUP62 plays a critical role in regulating the translation of miR-21, a microRNA that is involved in cell proliferation and survival. The authors showed that NUP62 interacts with miR-21 and prevents its translation into the nucleus, leading to the conclusion that NUP62 is a negative regulator of miR-21 translation.

Another study published in the journal PLoS One investigated the role of NUP62 in regulating miRNA translation in cancer cells. The authors found that NUP62 was highly expressed in human cancer tissues and that its expression was associated with poor prognosis in cancer patients. They also showed that NUP62 was involved in the translation of miR-18a, a microRNA that is known to suppress cancer cell growth and angiogenesis.

NUP62 has also been investigated as a potential drug target in cancer. One study published in the journal Cancer Research found that NUP62 was highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. The authors also showed that NUP62 was involved in the regulation of miRNA translation in cancer cells, and that inhibition of NUP62 increased the translation of miR-18a, a microRNA that is known to suppress cancer cell growth.

In addition to its potential as a drug target, NUP62 has also been investigated as a biomarker for cancer. One study published in the journal Clinical Cancer Research found that NUP62 was significantly increased in various types of cancer, including breast, ovarian, and colorectal cancer. . The authors also showed that NUP62 was associated with poor prognosis in cancer patients, and that its expression was independent of clinical stage and other traditional biomarkers.

Overall, NUP62 is a well-studied protein that plays a critical role in regulating the movement of RNA into the nucleus. Its function as a negative regulator of miRNA translation has been investigated extensively, and several studies have suggested that it may be a potential drug target and biomarker for cancer. Further research is needed to fully understand its mechanisms of action and its potential as a therapeutic agent.

Protein Name: Nucleoporin 62

Functions: Essential component of the nuclear pore complex (PubMed:1915414). The N-terminal is probably involved in nucleocytoplasmic transport (PubMed:1915414). The C-terminal is involved in protein-protein interaction probably via coiled-coil formation, promotes its association with centrosomes and may function in anchorage of p62 to the pore complex (PubMed:1915414, PubMed:24107630). Plays a role in mitotic cell cycle progression by regulating centrosome segregation, centriole maturation and spindle orientation (PubMed:24107630). It might be involved in protein recruitment to the centrosome after nuclear breakdown (PubMed:24107630)

The "NUP62 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUP62 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets